T1	Participants 129 210	patients with non-small-cell lung cancer after failure of first-line chemotherapy
T2	Participants 351 399	patients with non-small-cell lung cancer (NSCLC)
T3	Participants 662 782	patients with advanced NSCLC, EGFR wild-type or unknown, PS 0-2, in whom initial cisplatin-based chemotherapy had failed
T4	Participants 1291 1303	147 patients
T5	Participants 1321 1384	median age: 60Â±8 years, PS 0/1/2: 44/83/20 patients; males: 78%
